Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-r8w4l Total loading time: 0 Render date: 2025-03-09T17:26:10.191Z Has data issue: false hasContentIssue false

5 - Alzheimer's disease

Published online by Cambridge University Press:  31 July 2009

By
Brandy R. Matthews  and
Bruce L. Miller
Edited by
Bruce L. Miller  and
Bradley F. Boeve
Bruce L. Miller
Affiliation:
University of California, San Francisco
Bradley F. Boeve
Affiliation:
Mayo Foundation, Minnesota
Get access

Summary

Introduction

While dementia is characterized by a change in cognition that is sufficient to adversely affect a person's daily function in the absence of an acute confusional state or delirium, Alzheimer's disease (AD) more specifically refers to dementia that is slowly progressive with prominent memory dysfunction occurring early in the clinical course. Alois Alzheimer initially described the illness in 1901 with the clinical case of Auguste D., a 51-year-old woman with cognitive disturbance, disorientation, delusions, aphasia and behavioral dyscontrol. A postmortem presentation followed in 1906 and revealed the presenile dementia to be associated with striking generalized cortical atrophy and unique neuropathological changes. In a subsequent 1911 publication, Dr. Alzheimer described in histological detail the now disease-defining neurofibrillary tangles (NFT) and neuritic plaques observed at autopsy, with apparent surprise that the eponymous “Alzheimer's disease” had already been suggested in a textbook by Kraepelin in 1910. Alzheimer's disease now represents the leading cause of dementia worldwide and is a well-known cause of death, disability, and financial burden across cultures.

Epidemiology

In 1990, 4 million people in the USA were estimated to have AD, with an associated projection that this number would escalate to 14 million by 2050. The incidence of AD is age related, doubling every 5 years after the age of 65 years.

Type
Chapter
Information
The Behavioral Neurology of Dementia , pp. 56 - 73
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Morris, J.Clinical presentation and course of Alzheimer disease. In Terry, R, Katzman, R, Bick, K, Sisodia, S (eds.) Alzheimer Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:11–24.Google Scholar
Moller, HJ, Graeber, MB.The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 1998;248(3):111–22.Google ScholarPubMed
Ernst, RL, Hay, JW.Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord 1997;11(Suppl 6):135–45.Google ScholarPubMed
Ferri, CP, Prince, M, Brayne, Cet al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112–17.CrossRefGoogle ScholarPubMed
Mayeux, R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81–104.CrossRefGoogle ScholarPubMed
Brookmeyer, R, Gray, S, Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88(9):1337–42.CrossRefGoogle ScholarPubMed
Kukull, WA, Ganguli, M. Epidemiology of dementia: concepts and overview. Neurol Clin 2000;18(4):923–50.CrossRefGoogle ScholarPubMed
Bachman, DL, Wolf, PA, Linn, Ret al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992;42(1):115–19.CrossRefGoogle ScholarPubMed
Kokmen, E, Beard, CM, Offord, KP, Kurland, LT. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology 1989;39(6):773–6.CrossRefGoogle Scholar
Miech, RA, Breitner, JC, Zandi, PPet al. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology 2002; 58(2):209–18.CrossRefGoogle ScholarPubMed
Ruitenberg, A, Ott, A, Swieten, JC, Hofman, A, Breteler, MM. Incidence of dementia: does gender make a difference?Neurobiol Aging 2001;22(4):575–80.CrossRefGoogle Scholar
Tang, MX, Cross, P, Andrews, Het al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56(1):49–56.CrossRefGoogle ScholarPubMed
Perkins, P, Annegers, JF, Doody, RSet al. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology 1997;49(1):44–50.CrossRefGoogle Scholar
Wolfson, C, Wolfson, DB, Asgharian, Met al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344(15):1111–16.CrossRefGoogle Scholar
Helmer, C, Joly, P, Letenneur, L, Commenges, D, Dartigues, JF. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154(7):642–8.CrossRefGoogle ScholarPubMed
Waring, SC, Doody, RS, Pavlik, VN, Massman, PJ, Chan, W. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord 2005;19(4):178–83.CrossRefGoogle ScholarPubMed
Borenstein, AR, Copenhaver, CI, Mortimer, JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(1):63–72.CrossRefGoogle ScholarPubMed
Mayeux, R, Ottman, R, Maestre, Get al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45(Pt 1):555–7.CrossRefGoogle ScholarPubMed
Jordan, BD, Relkin, NR, Ravdin, LDet al. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997;278(2):136–40.CrossRefGoogle ScholarPubMed
Plassman, BL, Havlik, RJ, Steffens, DCet al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000;55(8):1158–66.CrossRefGoogle ScholarPubMed
Guo, Z, Cupples, , Kurz, Aet al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000; 54(6):1316–23.CrossRefGoogle ScholarPubMed
Luchsinger, JA, Tang, MX, Shea, S, Mayeux, R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63(7):1187–92.CrossRefGoogle ScholarPubMed
Craft, S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006;20(4):298–301.CrossRefGoogle ScholarPubMed
Decarli, C. Vascular factors in dementia: an overview. J Neurol Sci 2004;226(1–2):19–23.CrossRefGoogle ScholarPubMed
Breteler, MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21(2):153–60.CrossRefGoogle Scholar
Kivipelto, M, Helkala, EL, Hanninen, Tet al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001;56(12):1683–9.CrossRefGoogle ScholarPubMed
Petrovitch, H, White, LR, Izmirilian, Get al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging 2000;21(1):57–62.Google ScholarPubMed
Wolf, H, Julin, P, Gertz, HJ, Winblad, B, Wahlund, LO. Intracranial volume in mild cognitive impairment, Alzheimer's disease and vascular dementia: evidence for brain reserve?Int J Geriatr Psychiatry 2004; 19(10):995–1007.CrossRefGoogle ScholarPubMed
Beeri, MS, Davidson, M, Silverman, JMet al. Relationship between body height and dementia. Am J Geriatr Psychiatry 2005;13(2):116–23.CrossRefGoogle ScholarPubMed
Abbott, RD, White, LR, Ross, GWet al. Height as a marker of childhood development and late-life cognitive function: the Honolulu-Asia Aging Study. Pediatrics 1998;102(Pt 1):602–9.CrossRefGoogle ScholarPubMed
Wilson, RS, Scherr, PA, Bienias, JLet al. Socioeconomic characteristics of the community in childhood and cognition in old age. Exp Aging Res 2005;31(4):393–407.CrossRefGoogle ScholarPubMed
Hall, KS, Gao, S, Unverzagt, FW, Hendrie, HC. Low education and childhood rural residence: risk for Alzheimer's disease in African Americans. Neurology 2000;54(1):95–9.CrossRefGoogle ScholarPubMed
Moceri, VM, Kukull, WA, Emanuel, I, Belle, G, Larson, EB. Early-life risk factors and the development of Alzheimer's disease. Neurology 2000;54(2):415–20.CrossRefGoogle ScholarPubMed
Wilson, RS, Scherr, PA, Hoganson, Get al. Early life socioeconomic status and late life risk of Alzheimer's disease. Neuroepidemiology 2005;25(1):8–14.CrossRefGoogle ScholarPubMed
Kaplan, GA, Turrell, G, Lynch, JWet al. Childhood socioeconomic position and cognitive function in adulthood. Int J Epidemiol 2001;30(2):256–63.CrossRefGoogle ScholarPubMed
Mortimer, JA. Brain reserve and the clinical expression of Alzheimer's disease. Geriatrics 1997;52(Suppl 2):S50–3.Google ScholarPubMed
Qiu, C, Backman, L, Winblad, B, Aguero-Torres, H, Fratiglioni, L. The influence of education on clinically diagnosed dementia incidence and mortality data from the Kungsholmen Project. Arch Neurol 2001; 58(12):2034–9.CrossRefGoogle ScholarPubMed
Roe, C, Xiong, C, Miller, J, Morris, J. Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 2007;68(3):223–8.CrossRefGoogle ScholarPubMed
Kittner, SJ, White, LR, Farmer, MEet al. Methodological issues in screening for dementia: the problem of education adjustment. J Chronic Dis 1986;39(3):163–70.CrossRefGoogle ScholarPubMed
Zhang, MY, Katzman, R, Salmon, Det al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990;27(4):428–37.CrossRefGoogle Scholar
Stern, Y, Gurland, B, Tatemichi, TKet al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994;271(13):1004–10.CrossRefGoogle ScholarPubMed
Karp, A, Kareholt, I, Qiu, Cet al. Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. Am J Epidemiol 2004;159(2):175–83.CrossRefGoogle ScholarPubMed
Stern, Y, Albert, S, Tang, MX, Tsai, WY. Rate of memory decline in AD is related to education and occupation: cognitive reserve?Neurology 1999;53(9):1942–7.CrossRefGoogle ScholarPubMed
Stern, Y, Habeck, C, Moeller, Jet al. Brain networks associated with cognitive reserve in healthy young and old adults. Cereb Cortex 2005;15(4):394–402.CrossRefGoogle ScholarPubMed
Plassman, BL, Welsh, KA, Helms, Met al. Intelligence and education as predictors of cognitive state in late life: a 50-year follow-up. Neurology 1995;45(8):1446–50.CrossRefGoogle Scholar
Luchsinger, JA, Mayeux, R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004;3(10):579–87.CrossRefGoogle ScholarPubMed
Deng, J, Zhou, DH, Li, Jet al. A 2-year follow-up study of alcohol consumption and risk of dementia. Clin Neurol Neurosurg 2006;108(4):378–83.CrossRefGoogle Scholar
Ruitenberg, A, Swieten, JC, Witteman, JCet al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359(9303):281–6.CrossRefGoogle ScholarPubMed
Mukamal, KJ, Kuller, LH, Fitzpatrick, ALet al. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003;289(11):1405–13.CrossRefGoogle ScholarPubMed
Laitinen, MH, Ngandu, T, Rovio, Set al. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement Geriatr Cogn Disord 2006;22(1):99–107.CrossRefGoogle Scholar
Morris, MC, Evans, DA, Bienias, JLet al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003;60(2):194–200.CrossRefGoogle ScholarPubMed
Morris, MC, Evans, DA, Bienias, JLet al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60(7):940–6.CrossRefGoogle ScholarPubMed
Rovio, S, Kareholt, I, Helkala, ELet al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 2005;4(11):705–11.CrossRefGoogle Scholar
Larson, EB, Wang, L, Bowen, JDet al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144(2):73–81.CrossRefGoogle ScholarPubMed
Fratiglioni, L, Paillard-Borg, S, Winblad, B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004;3(6):343–53.CrossRefGoogle ScholarPubMed
Wilson, RS, Bennett, DA, Bienias, JLet al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002;59(12):1910–14.CrossRefGoogle Scholar
Gatz, M. Educating the brain to avoid dementia: can mental exercise prevent Alzheimer disease?PLoS Med 2005;2(1):e7.CrossRefGoogle ScholarPubMed
Bertram, L, Tanzi, RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115(6):1449–57.CrossRefGoogle ScholarPubMed
Gatz, M, Reynolds, CA, Fratiglioni, Let al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63(2):168–74.CrossRefGoogle ScholarPubMed
Goate, A, Chartier-Harlin, MC, Mullan, Met al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349(6311):704–6.CrossRefGoogle ScholarPubMed
Sherrington, R, Rogaev, EI, Liang, Yet al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375(6534):754–60.CrossRefGoogle ScholarPubMed
Levy-Lahad, E, Wasco, W, Poorkaj, Pet al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269(5226):973–7.CrossRefGoogle ScholarPubMed
Rogaeva, EA, Fafel, KC, Song, YQet al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 2001;57(4):621–5.CrossRefGoogle Scholar
Wisniewski, K, Wisniewski, H, Wen, G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278–82.CrossRefGoogle ScholarPubMed
Evenhuis, HM. The natural history of dementia in Down's syndrome. Arch Neurol 1990;47(3):263–7.CrossRefGoogle Scholar
Schupf, N, Kapell, D, Nightingale, Bet al. Specificity of the fivefold increase in AD in mothers of adults with Down syndrome. Neurology 2001;57(6):979–84.CrossRefGoogle ScholarPubMed
Corder, EH, Saunders, AM, Strittmatter, WJet al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261(5123):921–3.CrossRefGoogle ScholarPubMed
Poirier, J, Davignon, J, Bouthillier, Det al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342(8873):697–9.CrossRefGoogle ScholarPubMed
Slooter, AJ, Cruts, M, Kalmijn, Set al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998;55(7):964–8.CrossRefGoogle ScholarPubMed
Farrer, , Cupples, , Haines, JLet al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278(16):1349–56.CrossRefGoogle ScholarPubMed
Meyer, MR, Tschanz, JT, Norton, MCet al. APOE genotype predicts when – not whether – one is predisposed to develop Alzheimer disease. Nat Genet 1998;19(4):321–2.CrossRefGoogle Scholar
Rogaeva, E, Meng, Y, Lee, JHet al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39(2):168–77.CrossRefGoogle ScholarPubMed
Scherzer, CR, Offe, K, Gearing, Met al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 2004;61(8):1200–5.CrossRefGoogle ScholarPubMed
Dodson, SE, Gearing, M, Lippa, CFet al. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol 2006;65(9):866–72.CrossRefGoogle ScholarPubMed
Corey-Bloom, J. Alzheimer's Disease. In Miller, A (ed.) Continuum: Dementia. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:29–57.Google Scholar
Graeber, MB, Mehraein, P. Reanalysis of the first case of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999;249 (Suppl 3):10–13.CrossRefGoogle ScholarPubMed
Haass, C, Schlossmacher, MG, Hung, AYet al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992;359(6393):322–5.CrossRefGoogle ScholarPubMed
Blessed, G, Tomlinson, B, Roth, M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797–811.CrossRefGoogle ScholarPubMed
Bayer, TA, Wirths, O, Majtenyi, Ket al. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 2001;11(1):1–11.CrossRefGoogle ScholarPubMed
Hardy, J, Selkoe, DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353–6.CrossRefGoogle ScholarPubMed
Walsh, DM, Selkoe, DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44(1):181–93.CrossRefGoogle ScholarPubMed
Iqbal, K, Alonso Adel, C, Chen, Set al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005;1739(2–3):198–210.CrossRefGoogle ScholarPubMed
Braak, E, Griffing, K, Arai, Ket al. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 3):14–22.CrossRefGoogle ScholarPubMed
Blennow, K, Leon, MJ, Zetterberg, H. Alzheimer's disease. Lancet 2006;368(9533):387–403.CrossRefGoogle Scholar
Hyman, BT, Hoesen, GW, Damasio, AR, Barnes, CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225(4667):1168–70.CrossRefGoogle ScholarPubMed
Fuller, G, Goodman, J. Neurodegenerative disorders. Practical Review of Neuropathology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:257–264.Google Scholar
Mesulam, M, Shaw, P, Mash, D, Weintraub, S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004;55(6):815–28.CrossRefGoogle ScholarPubMed
Storga, D, Vrecko, K, Birkmayer, JG, Reibnegger, G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 1996;203(1):29–32.CrossRefGoogle ScholarPubMed
Reinikainen, KJ, Paljarvi, L, Huuskonen, Met al. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J Neurol Sci 1988;84(1):101–16.CrossRefGoogle ScholarPubMed
Reinikainen, KJ, Soininen, H, Riekkinen, PJ. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res 1990;27(4):576–86.CrossRefGoogle ScholarPubMed
Keller, JN. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res Rev 2006; 5(1):1–13.CrossRefGoogle ScholarPubMed
Khachaturian, ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42(11):1097–105.CrossRefGoogle ScholarPubMed
Mirra, SS, Heyman, A, McKeel, Det al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41(4):479–86.CrossRefGoogle Scholar
Braak, H, Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239–59.CrossRefGoogle Scholar
The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18(4 Suppl):S1–2.
Gorno-Tempini, ML, Dronkers, NF, Rankin, KPet al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55(3):335–46.CrossRefGoogle ScholarPubMed
McMonagle, P, Deering, F, Berliner, Y, Kertesz, A. The cognitive profile of posterior cortical atrophy. Neurology 2006;66(3):331–8.CrossRefGoogle ScholarPubMed
Lyketsos, CG, Lopez, O, Jones, Bet al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288(12):1475–83.CrossRefGoogle ScholarPubMed
Tatsch, MF, Bottino, CM, Azevedo, Det al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006;14(5):438–45.CrossRefGoogle ScholarPubMed
Cummings, JL. Alzheimer's disease. N Engl J Med 2004;351(1):56–67.CrossRefGoogle ScholarPubMed
Ortiz, F, Fitten, LJ, Cummings, JL, Hwang, S, Fonseca, M. Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006; 21(4):263–73.CrossRefGoogle Scholar
Chow, TW, Liu, CK, Fuh, JLet al. Neuropsychiatric symptoms of Alzheimer's disease differ in Chinese and American patients. Int J Geriatr Psychiatry 2002; 17(1):22–8.CrossRefGoogle ScholarPubMed
Cummings, JL, Mega, M, Gray, Ket al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308–14.CrossRefGoogle ScholarPubMed
Tang-Wai, DF, Graff-Radford, NR, Boeve, BFet al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004; 63(7):1168–74.CrossRefGoogle ScholarPubMed
Boeve, BF, Maraganore, DM, Parisi, JEet al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999;53(4):795–800.CrossRefGoogle ScholarPubMed
Caselli, RJ, Stelmach, GE, Caviness, JNet al. A kinematic study of progressive apraxia with and without dementia. Mov Disord 1999;14(2):276–87.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
Johnson, JK, Head, E, Kim, R, Starr, A, Cotman, CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999;56(10):1233–9.CrossRefGoogle ScholarPubMed
Kramer, JH, Miller, BL. Alzheimer's disease and its focal variants. Semin Neurol 2000;20(4):447–54.CrossRefGoogle ScholarPubMed
,American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press; 1994.
McKhann, G, Drachman, D, Folstein, Met al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939–44.CrossRefGoogle ScholarPubMed
Caselli, RJ, Beach, TG, Yaari, R, Reiman, EM. Alzheimer's disease a century later. J Clin Psychiatry 2006;67(11):1784–800.CrossRefGoogle ScholarPubMed
Barker, WW, Luis, CA, Kashuba, Aet al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;16(4):203–12.CrossRefGoogle ScholarPubMed
Caviness, JN. Myoclonus and neurodegenerative disease: what's in a name?Parkinsonism Relat Disord 2003;9(4):185–92.CrossRefGoogle Scholar
Attems, J, Konig, C, Huber, M, Lintner, F, Jellinger, KA. Cause of death in demented and non-demented elderly inpatients; an autopsy study of 308 cases. J Alzheimer's Dis 2005;8(1):57–62.CrossRefGoogle ScholarPubMed
Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–98.CrossRefGoogle ScholarPubMed
Kokmen, E, Smith, GE, Petersen, RC, Tangalos, E, Ivnik, RC. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991;48(7):725–8.CrossRefGoogle ScholarPubMed
Mungas, D, Marshall, SC, Weldon, M, Haan, M, Reed, BR. Age and education correction of Mini-Mental State Examination for English and Spanish-speaking elderly. Neurology 1996;46(3):700–6.CrossRefGoogle ScholarPubMed
Braaten, AJ, Parsons, TD, McCue, R, Sellers, A, Burns, WJ. Neurocognitive differential diagnosis of dementing diseases: Alzheimer's dementia, vascular dementia, frontotemporal dementia, and major depressive disorder. Int J Neurosci 2006;116(11):1271–93.CrossRefGoogle ScholarPubMed
Crowell, TA, Luis, CA, Cox, , Mullan, M. Neuropsychological comparison of Alzheimer's disease and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007;23(2):120–5.CrossRefGoogle ScholarPubMed
Diehl, J, Monsch, AU, Aebi, Cet al. Frontotemporal dementia, semantic dementia, and Alzheimer's disease: the contribution of standard neuropsychological tests to differential diagnosis. J Geriatr Psychiatry Neurol 2005;18(1):39–44.CrossRefGoogle ScholarPubMed
Rascovsky, K, Salmon, DP, Hansen, , Thal, LJ, Galasko, D. Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Neuropsychology 2007;21(1):20–30.CrossRefGoogle ScholarPubMed
Morris, JC, Heyman, A, Mohs, RCet al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39(9):1159–65.Google Scholar
Katzman, R, Brown, T, Fuld, Pet al. Validation of a short Orientation–Memory–Concentration Test of cognitive impairment. Am J Psychiatry 1983;140(6):734–9.Google Scholar
Kaplan, E, Goodglass, H, Weintraub, S. The Boston Naming Test. Boston, MA: Veterans Administration Medical Center; 1978.Google Scholar
Berg, L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24(4):637–9.Google Scholar
Morris, JC, Weintraub, S, Chui, HCet al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20(4):210–16.CrossRefGoogle ScholarPubMed
Wechsler, D, Stone, C.Manual: Wechsler Memory Scale. New York: Psychological Corporation; 1973.Google Scholar
Armitage, S. An analysis of certain psychological tests used in evaluation of brain injury. Psych Mono 1946;60:1–48.Google Scholar
Wechsler, D. Manual: Wechsler Adult Intelligence Scale. New York: Psychological Corporation; 1955.Google Scholar
Kaufer, DI, Cummings, JL, Ketchel, Pet al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12(2):233–9.CrossRefGoogle ScholarPubMed
Pfeffer, RI, Kurosaki, TT, Harrah, CH, Chance, JM, Filos, S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37(3):323–9.CrossRefGoogle Scholar
Sheikh, J, Yesavage, J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In Brink, T (ed.) Clinical Gerontology: A Guide to Assessment and Intervention. New York: Haworth Press; 1986:165–173.Google Scholar
Knopman, DS, DeKosky, ST, Cummings, JLet al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143–53.CrossRefGoogle Scholar
,American Academy of Neurology. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter for diagnosis and evaluation of dementia. [Summary statement.] Neurology 1994;44(11):2203–6.
Mendez, MF, Catanzaro, P, Doss, RCet al. Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol 1994;7(4):230–3.CrossRefGoogle ScholarPubMed
Lozsadi, DA, Larner, AJ. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement Geriatr Cogn Disord 2006;22(2):121–4.CrossRefGoogle ScholarPubMed
Hulstaert, F, Blennow, K, Ivanoiu, Aet al. Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 1999; 52(8):1555–62.CrossRefGoogle ScholarPubMed
Shoji, M, Matsubara, E, Kanai, Met al. Combination assay of CSF tau, A beta 1–40 and A beta 1–42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 1998;158(2):134–40.CrossRefGoogle Scholar
Gomez-Tortosa, E, Gonzalo, I, Fanjul, Set al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 2003;60(9):1218–22.CrossRefGoogle ScholarPubMed
Sunderland, T, Linker, G, Mirza, Net al. Decreased beta-amyloid 1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289(16):2094–103.CrossRefGoogle ScholarPubMed
Hampel, H, Buerger, K, Zinkowski, Ret al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004;61(1):95–102.CrossRefGoogle ScholarPubMed
Hansson, O, Zetterberg, H, Buchhave, Pet al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5(3):228–34.CrossRefGoogle ScholarPubMed
Wallin, AK, Blennow, K, Andreasen, N, Minthon, L. CSF biomarkers for Alzheimer's disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006;21(3):131–8.CrossRefGoogle Scholar
Zakzanis, KK, Graham, SJ, Campbell, Z. A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile. Neuropsychol Rev 2003;13(1):1–18.CrossRefGoogle ScholarPubMed
Yavuz, BB, Ariogul, S, Cankurtaran, Met al. Hippocampal atrophy correlates with the severity of cognitive decline. Int Psychogeriatr 2006:19:767–77.CrossRefGoogle ScholarPubMed
Laakso, MP, Partanen, K, Riekkinen, Pet al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996;46(3):678–81.CrossRefGoogle ScholarPubMed
Frisoni, GB, Laakso, MP, Beltramello, Aet al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology 1999;52(1):91–100.CrossRefGoogle ScholarPubMed
Nagy, Z, Hindley, NJ, Braak, Het al. Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by “stages”: a prospective study. Dement Geriatr Cogn Disord 1999;10(2):109–14.CrossRefGoogle ScholarPubMed
Pol, , Hensel, A, Barkhof, Fet al. Hippocampal atrophy in Alzheimer disease: age matters. Neurology 2006;66(2):236–8.Google ScholarPubMed
Jack, CR, Petersen, RC, Xu, YCet al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52(7):1397–403.CrossRefGoogle ScholarPubMed
deToledo-Morrell, L, Stoub, TR, Bulgakova, Met al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004;25(9):1197–203.CrossRefGoogle ScholarPubMed
Mattman, A, Feldman, H, Forster, Bet al. Regional HmPAO SPECT and CT measurements in the diagnosis of Alzheimer's disease. Can J Neurol Sci 1997;24(1):22–8.CrossRefGoogle Scholar
Gool, WA, Walstra, GJ, Teunisse, Set al. Diagnosing Alzheimer's disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J Neurol 1995;242(6):401–5.CrossRefGoogle ScholarPubMed
Bonte, FJ, Weiner, MF, Bigio, EH, White, CL. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 1997;202(3):793–7.CrossRefGoogle ScholarPubMed
Herholz, K, Salmon, E, Perani, Det al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17(1):302–16.CrossRefGoogle ScholarPubMed
Hoffman, JM, Welsh-Bohmer, KA, Hanson, Met al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41(11):1920–8.Google ScholarPubMed
Chetelat, G, Desgranges, B, Sayette, Vet al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?Neurology 2003;60(8):1374–7.CrossRefGoogle ScholarPubMed
Klunk, WE, Engler, H, Nordberg, Aet al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306–19.CrossRefGoogle ScholarPubMed
Shoghi-Jadid, K, Small, GW, Agdeppa, EDet al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10(1):24–35.CrossRefGoogle ScholarPubMed
Kung, MP, Hou, C, Zhuang, ZP, Skovronsky, D, Kung, HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res 2004; 1025(1–2):98–105.CrossRefGoogle ScholarPubMed
Engler, H, Forsberg, A, Almkvist, Oet al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129(Pt 11):2856–66.CrossRefGoogle ScholarPubMed
Small, GW, Kepe, V, Barrio, JR. Seeing is believing: neuroimaging adds to our understanding of cerebral pathology. Curr Opin Psychiatry 2006;19(6):564–9.CrossRefGoogle ScholarPubMed
Lockhart, A. Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today 2006; 11(23–24):1093–9.CrossRefGoogle ScholarPubMed
Birks, J.Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593.Google Scholar
Bullock, R, Touchon, J, Bergman, Het al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21(8):1317–27.CrossRefGoogle Scholar
Bullock, R, Dengiz, A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59(7):817–22.CrossRefGoogle ScholarPubMed
Rosler, M, Anand, R, Cicin-Sain, Aet al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318(7184):633–8.CrossRefGoogle ScholarPubMed
Raskind, MA, Peskind, ER, Wessel, T, Yuan, W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54(12):2261–8.CrossRefGoogle ScholarPubMed
Doody, RS, Stevens, JC, Beck, Cet al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1154–66.CrossRefGoogle Scholar
Kmietowicz, Z. NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ 2005;330(7490):495.Google ScholarPubMed
Harkany, T, Abraham, I, Timmerman, Wet al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000;12(8):2735–45.CrossRefGoogle ScholarPubMed
Topper, R, Gehrmann, J, Banati, Ret al. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol (Berl) 1995;89(1):23–8.CrossRefGoogle ScholarPubMed
Couratier, P, Lesort, M, Sindou, Pet al. Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 1996;27(3):259–73.CrossRefGoogle ScholarPubMed
Wilcock, GK. Memantine for the treatment of dementia. Lancet Neurol 2003;2(8):503–5.CrossRefGoogle ScholarPubMed
Tariot, PN, Farlow, MR, Grossberg, GTet al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317–24.CrossRefGoogle ScholarPubMed
Lyketsos, CG, Sheppard, JM, Steele, CDet al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease Study. Am J Psychiatry 2000;157(10):1686–9.CrossRefGoogle ScholarPubMed
Taragano, FE, Lyketsos, CG, Mangone, CA, Allegri, RF, Comesana-Diaz, E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997;38(3):246–52.CrossRefGoogle ScholarPubMed
Alexopoulos, GS, Jeste, DV, Chung, Het al. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005;(Spec No):6–22.Google ScholarPubMed
Sink, KM, Holden, KF, Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293(5):596–608.CrossRefGoogle Scholar
Schneider, LS, Tariot, PN, Dagerman, KSet al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355(15):1525–38.CrossRefGoogle ScholarPubMed
Wang, PS, Schneeweiss, S, Avorn, Jet al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22):2335–41.CrossRefGoogle ScholarPubMed
Beier, MT. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacotherapy 2007;27(3):399–411.CrossRefGoogle ScholarPubMed
Dubinsky, RM, Stein, AC, Lyons, K. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;54(12):2205–11.CrossRefGoogle ScholarPubMed
Wang, C, Kosinski, C, Schwartzberg, J. Physician's Guide to Assessing and Counseling Older Drivers. Washington, DC:National Highway Traffic Safety Administration; 2003.Google Scholar
Friedland, RP, Koss, E, Kumar, Aet al. Motor vehicle crashes in dementia of the Alzheimer type. Ann Neurol 1988;24(6):782–6.CrossRefGoogle ScholarPubMed
Carr, DB, Duchek, J, Morris, JC. Characteristics of motor vehicle crashes of drivers with dementia of the Alzheimer type. J Am Geriatr Soc 2000;48(1):18–22.CrossRefGoogle ScholarPubMed
Molnar, FJ, Patel, A, Marshall, SC, Man-Son-Hing, M, Wilson, KG. Clinical utility of office-based cognitive predictors of fitness to drive in persons with dementia: a systematic review. J Am Geriatr Soc 2006;54(12):1809–24.CrossRefGoogle ScholarPubMed
Roberson, ED, Mucke, L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006;314(5800):781–4.CrossRefGoogle ScholarPubMed
Chang, WP, Koelsch, G, Wong, Set al. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 2004;89(6):1409–16.CrossRefGoogle ScholarPubMed
Etcheberrigaray, R, Tan, M, Dewachter, Iet al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 2004;101(30):11141–6.CrossRefGoogle ScholarPubMed
Schenk, D, Hagen, M, Seubert, P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16(5):599–606.CrossRefGoogle ScholarPubMed
Weiner, HL, Frenkel, D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006;6(5):404–16.CrossRefGoogle ScholarPubMed
Orgogozo, JM, Gilman, S, Dartigues, JFet al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61(1):46–54.CrossRefGoogle Scholar
Geerts, H. NC-531 (Neurochem). Curr Opin Investig Drugs 2004;5(1):95–100.Google Scholar
Crouch, PJ, Barnham, KJ, Bush, AI, White, AR. Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Drug News Perspect 2006;19(8):469–74.CrossRefGoogle ScholarPubMed
Engel, T, Goni-Oliver, P, Lucas, JJ, Avila, J, Hernandez, F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006;99(6):1445–55.CrossRefGoogle Scholar
Delanty, N, Vaughan, C. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1998;51(2):652.CrossRefGoogle ScholarPubMed
Szekely, CA, Thorne, JE, Zandi, PPet al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004;23(4):159–69.CrossRefGoogle ScholarPubMed
Aisen, PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 2002;1(5):279–84.CrossRefGoogle ScholarPubMed
Eriksen, JL, Sagi, SA, Smith, TEet al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003;112(3):440–9.CrossRefGoogle ScholarPubMed
Tang, MX, Jacobs, D, Stern, Yet al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348(9025):429–32.CrossRefGoogle ScholarPubMed
Henderson, VW, Paganini-Hill, A, Miller, BLet al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54(2):295–301.CrossRefGoogle ScholarPubMed
Engelhart, MJ, Geerlings, MI, Ruitenberg, Aet al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287(24):3223–9.CrossRefGoogle ScholarPubMed
Sano, M, Ernesto, C, Thomas, RGet al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336(17):1216–22.CrossRefGoogle ScholarPubMed
Lonn, E, Bosch, J, Yusuf, Set al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293(11):1338–47.Google ScholarPubMed
Jick, H, Zornberg, GL, Jick, SS, Seshadri, S, Drachman, DA. Statins and the risk of dementia. Lancet 2000;356(9242):1627–31.CrossRefGoogle Scholar
Yang, F, Lim, GP, Begum, ANet al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280(7):5892–901.CrossRefGoogle ScholarPubMed
Reddy, PH, McWeeney, S. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol Aging 2006;27(8):1060–77.CrossRefGoogle ScholarPubMed
Davidsson, P, Sjogren, M. Proteome studies of CSF in AD patients. Mech Ageing Dev 2006;127(2):133–7.CrossRefGoogle ScholarPubMed
Hye, A, Lynham, S, Thambisetty, Met al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006;129(Pt 11):3042–50.CrossRefGoogle ScholarPubMed
Mueller, SG, Weiner, MW, Thal, LJet al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15(4):869–77, xi–xii.CrossRefGoogle ScholarPubMed
Lopponen, M, Raiha, I, Isoaho, R, Vahlberg, T, Kivela, SL. Diagnosing cognitive impairment and dementia in primary health care: a more active approach is needed. Age Ageing 2003;32(6):606–12.CrossRefGoogle ScholarPubMed
Callahan, CM, Hendrie, HC, Tierney, WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 1995;122(6):422–9.CrossRefGoogle ScholarPubMed
Svansdottir, HB, Snaedal, J. Music therapy in moderate and severe dementia of Alzheimer's type: a case-control study. Int Psychogeriatr 2006;18(4):613–21.CrossRefGoogle ScholarPubMed
Rolland, Y, Pillard, F, Klapouszczak, Aet al. Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J Am Geriatr Soc 2007;55(2):158–65.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×